Apellis Pharmaceuticals Inc (APLS)
Industry Biotechnology
This stock can be held in an Investment ISA and an Investment Account
Sell
$15.00
Buy
$17.39
$-0.34 (-2.04%)
Apellis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company is engaged in the discovery and development of novel therapeutic compounds for autoimmune and inflammatory diseases.
Prices updated at 16 May 2025, 09:00 BST
| Prices minimum 15 mins delay
|
Prices in USD
Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and
- Key stats
- Price
- Fair value
- Dividends
- News
- Financials
- Valuation
- Profile
Profit margins
Valuation
Profit margins data table
| Year | Gross margin (%) | Operating margin (%) | Net margin (%) | EBITDA margin (%) | EBITDA |
|---|---|---|---|---|---|
| 2024 | 84.93 | -21.11 | -25.32 | -19.78 | -155m |
| 2023 | 85.25 | -130.39 | -133.29 | -124.85 | -495m |
| 2022 | 92.53 | -788.38 | -864.70 | -818.49 | -617m |
| 2021 | 92.19 | -805.67 | -1,121.27 | -1,098.61 | -731m |
| 2020 | 90.01 | -85.27 | -137.59 | -124.57 | -312m |
| 2019 | - | - | - | - | -299m |
| 2018 | - | - | - | - | -125m |
| 2017 | - | - | - | - | -51m |
| 2016 | - | - | - | - | -27m |
Valuation data table
| Year | Price / Sales | Price earnings | Price / Cash flow |
|---|---|---|---|
| 2025 | 2.63 | - | - |
| 2024 | 5.49 | - | - |
| 2023 | 25.45 | - | - |
| 2022 | 46.42 | - | - |
| 2021 | 14.82 | - | - |
| 2020 | 5,920.96 | - | - |
| 2019 | - | - | - |
| 2018 | - | - | - |
| 2017 | - | - | - |
Price/Forward earnings (YTD)
-10.91
Returns
Debt profile
Returns data table
| Year | Return on assets (%) | Return on equity (%) | Return on invested capital (%) |
|---|---|---|---|
| 2024 | -23.64 | -93.55 | -35.08 |
| 2023 | -68.26 | -290.14 | -177.47 |
| 2022 | -79.44 | -353.93 | -183.22 |
| 2021 | -81.02 | -370.20 | -148.71 |
| 2020 | -51.10 | -288.86 | -84.30 |
| 2019 | -102.81 | -312.20 | -160.58 |
| 2018 | -66.12 | -82.28 | -70.11 |
| 2017 | -48.68 | -126.44 | -76.29 |
| 2016 | -82.68 | - | - |
Debt profile data table
| Year | Financial leverage |
|---|---|
| 2024 | 3.87 |
| 2023 | 4.05 |
| 2022 | 4.48 |
| 2021 | 4.44 |
| 2020 | 4.70 |
| 2019 | 11.37 |
| 2018 | 1.26 |
| 2017 | 1.22 |
| 2016 | - |
The figures shown in the Profit Margins table EBITDA column are quoted in the currency of the stock selected.
